William Petty
Hematology & Oncology · Winston Salem, NCNPI 1164406690
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,959 of the $8,146 with a category attached, or 85.4%. 5 manufacturers reported payments, led by Amgen at 54.7% of the total. Reporting peaked in 2023 at $4,459 and has fallen 74.1% since, to $1,153 in 2025.
Across 6 payments — averaging $1357.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$4K
- Jazz Pharmaceuticals Inc.$3K
- Catalyst Pharmaceuticals, Inc.$1K
- Johnson & Johnson$22
- Pfizer$12
Across 34 payments — averaging $41,163 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$739K
- Merck$658K
- AbbVie$2K
What the payments were for
- Consulting fees$6,95985%
- Speaking & faculty fees$1,12514%
- Food & beverage$280%
- Education$340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 1 | $4,459 |
| Jazz Pharmaceuticals Inc. | 1 | $2,500 |
| Catalyst Pharmaceuticals, Inc. | 2 | $1,153 |
| Johnson & Johnson | 1 | $22 |
| Pfizer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,146 in reported general payments places this provider in the 70th percentile of 358 hematology & oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AlecensaAlectinib Hcl | 12 | $212,367 |
| LumakrasSotorasib | 12 | $74,434 |
| EliquisApixaban | 13 | $10,954 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 21 | $401 |
| Celecoxib | 16 | $391 |
| Dexamethasone | 19 | $355 |
| Levofloxacin | 13 | $347 |
| Prednisone | 80 | $288 |
| Gabapentin | 20 | $268 |
| Ondansetron Hcl | 33 | $265 |
| Prochlorperazine Maleate | 13 | $120 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenLumakras | $4,459 | $74,43412 claims |
| PfizerEliquis | $12 | $10,95413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 358 hematology & oncology providers in North Carolina.
Other hematology & oncology in Winston Salem
- Angela AlistarWinston Salem$509K
- Ravi PaluriWinston Salem$314K
- Caio Max Rocha LimaWinston Salem$110K
- Timothy PardeeWinston Salem$68K
- Leon Bernal-MizrachiWinston Salem$62K
- Matthew WieduwiltWinston Salem$36K
- John McKayWinston Salem$22K
- Amit MehtaCary$4.3M
- Michael MorseDurham$2.6M
- Shelbi AtrashCharlotte$994K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.